The Global Market for PAH Therapeutics is Projected to Reach US$6.1 Billion by 2022

High Unmet Treatment Needs & Discovery of New Disease Pathways for the Development of More Effective Drugs Drive the Pulmonary Arterial Hypertension Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Pulmonary Arterial Hypertension (PAH) Therapeutics market. The global market for PAH Therapeutics is projected to reach US$6.1 billion by 2022, driven by improving diagnosis rates and development of novel drugs as a result of progressive and measurable improvements in understanding and management of the disease from pathology, physiology and pharmacology perspectives.  

Pulmonary Arterial Hypertension (PAH) is characterized by abnormal high blood pressure in the pulmonary arteries that puts strain on the heart and eventually results in cardiac failure. Incidence of the disease is rare, affecting about 15-50 in a million people and increases with age. The symptoms of PAH are non-specific, similar to those of other heart and lung conditions, and range from fatigue and mild breathlessness during normal daily activity to right heart failure and limited exercise ability. Medication for PAH comprises vasodilators that aid in relaxing constricted pulmonary blood vessels, reducing symptoms and slowing the disease progression. The impact on market growth due to the loss of market exclusivity of major drugs such as Tracleer, is counterbalanced by the development and launch of innovative safer and efficient new drugs with low side effects. The market is characterized by intense competition among existing players and increase in research and development activities. In addition, adoption of combination therapy involving various drug combinations is expected to benefit market growth. Pediatric pulmonary arterial hypertension (PAH) stands out as a lucrative market opportunity.

Major drugs prescribed specifically for PAH fall under the broad categories - prostacyclin and its analogs, endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE-5) inhibitors, and Soluble Guanylate Cyclase (sGC) Stimulators. While Endothelin Receptor Antagonist (ERA) currently dominate the PAH therapeutics market, newer forms of administration of prostacyclin and its analogs are forecast to report stronger growth over the analysis period. Oral therapies form the most preferred mode of administration for treatment of PAH as they are relatively easier to administer and more effective than other routes of administration such as intravenous or inhaled.

As stated by the new market research report on Pulmonary Arterial Hypertension (PAH) Therapeutics, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market, with a CAGR of 7.7% over the analysis period, led by factors such as large population and healthcare burden; improving disease awareness; rising per capita healthcare spending as a result of growing income and affluence; government policy led development of healthcare infrastructure; and rise in risk factors for PAH such as use of methamphetamine and cocaine, high incidence of diseases like lupus, scleroderma, cirrhosis of the liver, HIV infection, and  portal hypertension.

Major players covered in the report include Actelion Pharmaceuticals Ltd., Bayer AG, Gilead Sciences, Inc., Pfizer Inc., United Therapeutics Corporation and Lung Biotechnology PBC.

The research report titled "Pulmonary Arterial Hypertension (PAH) Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World.   Analysis is further provided for the period 2009-2018 by dug brands / categories including by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC)  Stimulators (Riociguat).

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.

Comments

Post a Comment

Popular posts from this blog

The Global Market for Surfing is Projected to Reach US$9.5 Billion by 2022

Rise of Surfing as a Lifestyle Sport Among all Age Groups Drives the Global Surfing Market, According to a New Report by Global Industry Analysts, Inc. GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Surfing market. The global market for Surfing is projected to reach US$9.5 billion by 2022 , driven by the growing interest in surfing both as a leisure and sporting activity, increased accessibility to surfing through surf parks and surf pools and technology innovations focused on developing sophisticated surf-wear and surf-gear.                               Surfing is a surface water sport where a participant riding a board (the surfboard) is carried away by a breaking wave. The surfing industry continues to evolve, driven by sustained efforts of s...
Read more

The Global Market for Private Tutoring Services is Forecast to Reach US$227 Billion by 2022

Intense Competition among Students and the Growing Need to Achieve Academic Excellence Drive the Global Private Tutoring Market, According to a New Report by Global Industry Analysts, Inc. GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Private Tutoring market. The global market for Private Tutoring Services is forecast to reach US$227 billion by 2022 , driven by the need to keep pace with classroom teaching, improve overall competency and enhance knowledge and skill level. Education is considered the social ladder to achieve success in personal and professional life. Higher education is associated with increased opportunities in the labor market, high remunerations, and improved social standing. People are therefore investing heavily in children’s education, including private tutoring or private supplementary tutoring which is emerging as a major phenomenon in the global education system...
Read more
Image
The global market for Material Handling Equipment is projected to reach US$190.3 billion by 2025, driven by the strong emphasis shed on production and operational efficiency and worker safety. The concept of “last mile” is widely popularized in supply chain management and transportation planning for its ability to increase customer satisfaction and profitability. Automation, optimization and delivery route planning are therefore vital strategies adopted by companies to improve their last mile performance. Of equal importance are the “first mile” operations involving indoor material handling on the plant floor. Raw material being the primary and most importance element in manufacturing needs to move through multiple stages of production and final packaging in a smooth and seamless manner to prevent logistical bottlenecks in production. Timely handling of materials is important to ensure that right materials in right quantities are delivered to the right locations at the right ti...
Read more